Main Article Content

Raveendran K.C




Cancer is a major public health concern in both developed and developing countries. Now a days, the treatments of cancer categorizes   in to 5 classes, Surgery, Radiation, Chemotherapy, targeted and immunotherapy.  Cancer   chemotherapy   is   one   the   major   way to   treat   cancer without medical assistants. The main aim of the ideal cancer chemotherapy is to deliver the correct   amount of   drug   with   desired   controlled   rate   and  sufficiently  longer  duration  of  time  to  the  site  of  action(Tumor cells)to  obtain  the  desired  therapeutic response. Traditional cancer chemotherapy is based on the promise that tumor cells are more likely to be killed by anticancer drugs because of the faster proliferation of those cancer cells. However, in reality most of the drugs cannot differentiate cancer cells from the normal cells. This results in the undesirable effect of the drug because of the lack of selectivity. To minimize this risk, the development of tumor targeted drug delivery systems of anti-cancerous agents is necessary. The success of therapy depends on the selection of ideal carriers’ system that can deliver the drug selectively to tumor cells.  These carries include nanoparticles, nanotubes, nanorods, dendrimers, micelles, solid lipid nanoparticles, microspheres.

Abstract 49 | pdf Downloads 31


1. Zugagiotaj, Guedes. C, PonceS.FerrerI,Molina – Pinela S ,Paz-AresL.(2016)Current challenges in cancer treatment,Clin ther.;1-16
2. .Base Y.H,Park.K,(2011)targeted drug delivery to tumors: myths reality and possibility. J. control release; 153; 198-205.
3. Chen S. Zhao X,Chenj.KaznertsovaL,WongSS,(2010) Mechanism based tumor targeting drug delivery system.Validation of efficient vitamin receptor-mediated endocyosis and drug release,Bio conjugate Chem.;21:979-987.
4. Kakdi D, Jain D, Shrivastava V,Kakdi R,Patil A.T,(2011)Cancer therapeutics opportunities, challenges and advances in drug delivery, Journal of applied Pharmaceutical sciences.;01(09):01-10.
5. Nguyen T.K,(2011);Targeted nanoparticles for cancer therapy; promises and challenges, Nguyen j NanomedicNantechnol.2(5).
6. .Dharap S.S, Wang.Y, Chandana.P,Khanderej.j,Gunaseelan S, SinkoP.J,Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide,PNAS.2015;102(36):12962-12967.
7. .Danhier F, Ansorena E, SilvaJ.M,cocoR,BretonA.L,PreatV.A(2012) PLGA based nanoparticles: an over view of biomedical applications,J.cornet; 161:505-522.
8. Ruoslah E.RajotteD,(2000)An address system in the vasculature of normal tissues and tumors.Annu.Rev.Immunol;18:813-827.
9. Ren WX,Hanj,UhmS,jangYj,kangC,KimJ.H;(2015);Recent development of biotin conjugation in biological imaging, sensing and targeted delivery. Chem Commun.; 51(52):10403-10418.
10. Gabizon A,HarowitzAT,GorenD,Tzemachd,MandelbaumShavitF,Qazen M M,et al.(1999); Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes; in vitro studies, Biocojugate Chem.; 10:289-298. Ishida O, MaryumaK, Tanahashih,IwatsuruM,SasakiH,Eriguchi M;(2000) Liposomes bearing polyethylene glycol coupled transferrin with intracellular targeting property to the solid tumors in vivo, Pharm Res.,1;18:1042-1048.
11. FrankelA.E, PowellB.L, HallP.D, CaseL.D, Keittman R.J, :( 2002). Phase -1 trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukaemia.Clin.Oncol.;8:1004-1013.
12. Seymour BLW,Ferry DR, Anderson D, HesselwoodS,JulyanP.J,Poyner R, et al,(2002) Hepatic drug targeting:Phase-1 evaluation of polymer-bound doxorubicin, j.Clin.Oncol.;20:1668-1676.
13. Zhang W,RanS,SambadeM,HuangX,Thorpe PE,; (2002;)A monoclonal antibody that blocks VEGF binding to VEGFR 2(KDR/Flk-1) inhibit vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model,Angiogesis,5:35-44.
14. Noonberg SB,BenzCC,(2000).Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor sub family: role as anticancer agents,Drugs;59(4): 753-767.
15. Smith MR,(2000).Rituximab(monoclonal anti-CD 20 antibody): mechanism of action and resistance;Oncogene,;59(4):753-767.
16. Leonard J.P,LinkB.K,(2002)Immunotherapy of non-Hodgkin’s lymphoma with HLL-2(epratuzumab, an anti-CD22 monoclonal antibody) and HuID10 (apolizumab); Semen Oncol.:29(2) 81-86.